Evaluation of Using Topical Bromfenac as an Adjunctive Treatment with Intravitreal Ranibizumab for Diabetic Macular Edema

Résumé

Abstract Purpose To determine the safety and efficacy of adding topical bromfenac 0.09% in the treatment of diabetic macular edema. Methods Seventy patients (70 eyes) with centre involved diabetic macular edema (DME) with macular thickness (300-500um) were included. Patients were divided randomly into two groups; 35 eyes in each group. Both groups were treated with intravitreal ranibizumab monthly for three consecutive months. Bromfenac 0.09% eye drops twice daily was added to treatment of study group for six months from commencement of treatment. Efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, central retinal thickness and the need of re-injection. Results Patients treated with topical bromfenac in addition to intravitreal ranibizumab revealed significant improvement in visual acuity, more reduction in central and average macular thickness; and less tendency to need reinjection compared to those treated with ranibizumab alone (p 0.013, p 0.010 and p 0.022 respectively). Conclusion Topical bromfenac 0.09 % twice a day could enhance and sustain the efficacy of intravitreal ranibizumab in the treatment of diabetic macular edema without increase incidence of corneal side effects.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0